[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@occams_tooth Occam's Toothbrush

Occam's Toothbrush posts on X about $beam, $arwr, $ptct, $rna the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX -XX%
• X Month XXXXX -XX%
• X Months XXXXXXX +310%
• X Year XXXXXXX +29,893%

Mentions: X #

• X Week XX -XX%
• X Month XX -XX%
• X Months XXX +69%
• X Year XXX +4,200%

Followers: XXX #

• X Week XXX +2.70%
• X Month XXX +8.30%
• X Months XXX +466%
• X Year XXX +2,365%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence stocks XX% cryptocurrencies XXXXX% finance XXXX%

Social topic influence $beam 13.33%, $arwr 13.33%, $ptct 13.33%, $rna 13.33%, $150m 6.67%, $pfe 6.67%, target 6.67%, $100mtarget 6.67%, $regn 6.67%, $ions XXXX%

Top accounts mentioned or mentioned by @daphnezohar @lifescivc @samfazeli8 @brianskorney @yaronwerber @ericschmidt151 @mpreminger @jmaraganore @matteispaul @thedawnbell @colongracee @timopler @zhaoweiasu @captainrisky7 @semodough @seedy19tron @geneinvesting @kms_ghostt @artsstocks @markc_lvb

Top assets mentioned BEAM (BEAM) Arrowhead Research Corporation (ARWR) PTC Therapeutics, Inc. (PTCT) Avidity Biosciences, Inc. Common Stock (RNA) Pfizer, Inc. (PFE) Regeneron Pharmaceuticals Inc (REGN) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Denali Therapeutics Inc. Common Stock (DNLI) Royalty Pharma plc Class A Ordinary Shares (RPRX) CRISPR Therapeutics AG (CRSP) Wave Life Sciences Ltd. Ordinary Shares (WVE) Novartis AG (NVS) Merck & Co., Inc. (MRK) Cidara Therapeutics, Inc. (CDTX) Roivant Sciences Ltd. Common Shares (ROIV) Insmed, Inc. (INSM) BridgeBio Pharma, Inc. Common Stock (BBIO) Krystal Biotech, Inc. Common Stock (KRYS) Alnylam Pharmaceuticals, Inc. (ALNY)

Top Social Posts

Top posts by engagements in the last XX hours

"$150M UF for XX% co-co on a single target. The new high watermark for preclinical genetic medicine deals I think $BEAM $PFE at $100M/target was previous record holder $REGN"
X Link 2025-12-01T15:50Z XXX followers, XXX engagements

"Arrowhead $ARWR stock move is logical but timing is puzzling. APOC3 program seems better than Ionis $IONS and catalyst rich 2026 on the horizon (sHTG obesity CNS etc). But all of this was already known so why is the stock up XX% today"
X Link 2025-11-26T20:36Z XXX followers, XXX engagements

"I have never understood how PTCs small molecule splicing modulators can be specific for ONE snRNP at ONE exon in ONE gene in the entire genome. Seems very non-intuitive to me. Source: $PTCT R&D day"
X Link 2025-12-03T02:10Z XXX followers, XXX engagements

"$DNLI $RPRX is a good deal: X. $RPRX values tivi above street. $275M for X% royalty; assuming XX% margins tivi is worth $2B X. $DNLI up 7%. Good example for naysayers who say no such thing as non-dilutive financing. Thats true in theory but not for undervalued assets"
X Link 2025-12-05T13:38Z XXX followers, XXX engagements

"@GeneInvesting Great data and agree it seems differentiated vs $CRSP on X. Better efficacy (100% VOC free) X. Fewer days in / visits to hospital But busulfan conditioning will still limit adoption. $BEAM may well switch all Casgevy pts but hard to see a dramatic increase in class revenue"
X Link 2025-12-06T16:52Z XXX followers, XXX engagements

"Interesting that $ARWR benefited from the $WVE INHBE data earlier this week (up roughly $1B in mkt cap) but is not being dragged down by the STAT news article controversy"
X Link 2025-12-11T23:53Z XXX followers, 1062 engagements

"Not the key takeaway from the $RNA proxy but I find it hard to believe that the SpinCo Bryce therapeutics has a DCF value of $350M - preclinical programs - economics mostly partnered away - tiny populations (4K US pts) Cant imagine it will fare well on public markets"
X Link 2025-11-25T13:06Z XXX followers, XXX engagements

"80%+ improvement from first bid to final offer. Incredible compared to biopharma avg in XX (roughly 20%). $RNA $NVS was XX% higher than initial offer even thought there was only one bidder"
X Link 2025-12-05T23:25Z XXX followers, XXX engagements

"$ROIV investor day nice articulation of the switch from short the launch to own the launch Remarkable share price appreciation from post-data/pre-approval to revenue: $ALNY $ARGX $INSM Not in chart but other good examples imo: $BBIO $KRYS $PTCT"
X Link 2025-12-12T19:20Z XXX followers, XXX engagements